Key result
Biochemical characterization revealed that as few as five mutations in DRG1 can switch its binding specificity from DFRP1 to DFRP2.
This is the authors' abstract. We don't add key points for this paper.
Eukaryotes have two paralogous developmentally regulated GTP-binding (DRG) proteins: DRG1 and DRG2, both of which have a conserved binding partner called DRG family regulatory protein 1 and 2 (DFRP1 and DFRP2), respectively. DFRPs are important for the function of DRGs and interact with their respective DRG via a conserved region called the DFRP domain. Despite being highly similar, DRG1 and DRG2 have strict binding specificity for their respective DFRP. Using AlphaFold generated structure models of the human DRG/DFRP complexes, we have biochemically characterized their interactions and identified interface residues involved in determining specificity. This analysis revealed that as few as five mutations in DRG1 can switch binding from DFRP1 to DFRP2. Moreover, while DFRP1 binding confers increased stability and GTPase activity to DRG1, DFRP2 binding only supports increased stability. Overall, this work provides new insight into the structural determinants responsible for the binding specificities of the DRG/DFRP complexes.
This study identifies the structural determinants responsible for the binding specificities of human DRG/DFRP complexes, showing that five mutations can rewire DRG1 specificity.
No takes yet. Share an insight, caveat, or question.
Westrip et al. (2024) studied this question. Mutations in DRG1 was evaluated on Binding specificity and stability/GTPase activity. Biochemical characterization revealed that as few as five mutations in DRG1 can switch its binding specificity from DFRP1 to DFRP2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: